CVAC CureVac N.V. Stock Quote

CVAC [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	55.92%	Shs Outstand	213.08M	Perf Week	-9.02%
Market Cap	8.48B	Forward P/E	5.98	EPS next Y	6.66	Insider Trans	0.00%	Shs Float	90.88M	Perf Month	-27.74%
Income	-	PEG	-	EPS next Q	-0.73	Inst Own	23.50%	Short Float	4.75%	Perf Quarter	-20.61%
Sales	50.50M	P/S	168.02	EPS this Y	-26.40%	Inst Trans	0.05%	Short Ratio	6.51	Perf Half Y	-64.76%
Book/sh	-	P/B	-	EPS next Y	374.00%	ROA	-	Target Price	-	Perf Year	-23.42%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	37.54 - 151.80	Perf YTD	-50.88%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-14.20%	52W High	-73.77%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	6.07%	ATR	3.49
Employees	500	Current Ratio	-	Sales Q/Q	622.60%	Oper. Margin	-	RSI (14)	29.97	Volatility	10.62% 6.69%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	3.41	Prev Close	45.47
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	663.47K	Price	39.82
Recom	2.70	SMA20	-19.80%	SMA50	-32.95%	SMA200	-52.23%	Volume	2,263,288	Change	-12.43%

Jun-17-21

Downgrade

BofA Securities

Buy → Neutral

$50

Apr-26-21

Resumed

Credit Suisse

Underperform

Apr-26-21

Initiated

Guggenheim

Neutral

Dec-10-20

Downgrade

Credit Suisse

Neutral → Underperform

$50 → $47

Sep-08-20

Initiated

Jefferies

Hold

$58

Sep-08-20

Initiated

Credit Suisse

Neutral

$68

Sep-08-20

Initiated

BofA Securities

Buy

$70

Oct-14-21 10:41AM	The Petri Dish: Gene therapy startup launches, Charles River Labs sells two sites American City Business Journals
Oct-12-21 11:12AM	CureVac ditches first generation Covid vaccine to focus efforts on variant jab The Independent
11:10AM	Why CureVac Stock Is Tumbling Today Motley Fool
09:42AM	Why CureVac Shares Are Trading Lower Today Benzinga
08:43AM	CureVac Halts Its First mRNA-Based Covid Vaccine. The Stock Is Tumbling. Barrons.com
08:34AM	CureVac scraps its first-generation COVID-19 vaccine candidate, shares tumble Fortune
08:24AM	CureVac Drops Its First mRNA-Based Covid Vaccine, and the Stock Is Tumbling Barrons.com
07:20AM	CureVac stops development of its COVID-19 shot, will focus on new COVID-19 vaccine set for 2022 MarketWatch
07:15AM	CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology ACCESSWIRE
06:13AM	CureVac Stock Drops; Firm Ends Development of Covid mRNA Vaccine TheStreet.com
04:50AM	CureVac Slumps in Premarket; Tesla, GlaxoSmithKline Rise Investing.com
04:37AM	Premarket Movers Tuesday - CureVac, Nike, Tesla, Airbnb, MGM TheStreet.com
04:09AM	CureVac Slumps on Dropping Current Covid Candidate in Favor of New Jab Investing.com
Sep-27-21 10:31AM	10 Best German Stocks to Buy Now Insider Monkey
Sep-23-21 12:12PM	UPDATE 1-EU drugs regulator to decide on Pfizer vaccine booster in early October Reuters
Sep-14-21 09:54AM	CureVac Stock Falls as Company Cancels Vaccine Manufacturing Contracts Barrons.com -8.02%
07:49AM	CureVac slashes COVID-19 vaccine production plans Reuters
07:30AM	CureVac Streamlines European Network for mRNA Product Manufacturing ACCESSWIRE
Sep-07-21 04:05PM	'It's game over. It's mRNA or nothing:' Expert on future of vaccines Yahoo Finance
Sep-01-21 12:47PM	Glaxo (GSK), SK bioscience's COVID-19 Jab Enters Phase III Study Zacks +6.11%
Aug-31-21 07:15AM	CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet ACCESSWIRE -7.54%
Aug-30-21 07:15AM	CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic ACCESSWIRE
Aug-27-21 07:04AM	Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines? Motley Fool
Aug-19-21 09:30AM	Rentschler ready to start commercial production of CureVac COVID-19 shot Reuters
Aug-18-21 11:47AM	Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations Zacks
Aug-17-21 09:58AM	CureVac Says Second Covid-19 Vaccine Was Better in Preclinical Test Barrons.com +8.09%
07:50AM	CureVac (NASDAQ:CVAC) investors are sitting on a loss of 21% if they invested a year ago Simply Wall St.
Aug-16-21 10:40AM	CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update ACCESSWIRE
10:30AM	CureVac stock gains after upbeat preclinical data on COVID-19 vaccine candidate on primates MarketWatch
08:32AM	Nio Is Dropping, CureVac Is Popping and What Else Is Happening in the Stock Market Monday Barrons.com
07:15AM	Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study ACCESSWIRE
05:01AM	CureVac Stock Rises on Announcement of Positive Results for COVID Vaccines TheStreet.com
04:34AM	Premarket Movers Monday: CureVac, UWM Holdings, Oatly, Sesen Bio TheStreet.com
Jul-21-21 08:00PM	The race is on: CureVac seeks answers to vaccine disappointment Financial Times
Jul-20-21 11:01AM	Questor: our vaccine stocks are fine, but nothing can inoculate airlines against Covid uncertainty The Telegraph
Jul-10-21 06:00AM	Can CureVac Win Market Share With Only 48% Vaccine Efficacy? Motley Fool
Jul-07-21 12:56PM	Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More Zacks
Jul-04-21 07:31AM	Here's Why You Should Avoid CureVac Stock Like the Plague Motley Fool
06:00AM	Is CureVac a Bargain Bet on mRNA Vaccine Technology? Motley Fool
Jul-03-21 07:00AM	Moderna and Pfizer May Benefit From This Rival's Bad News Motley Fool
06:15AM	Can CureVac Recover After Its Vaccine Setback? Motley Fool
Jul-01-21 10:58AM	CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine Study Zacks -7.66%
09:03AM	Vaccine Makers Stocks Are Moving as Also-Rans Fight for Spots in the Market Barrons.com
04:34AM	Premarket Movers Thursday: CureVac, Walgreens, Micron TheStreet.com
03:52AM	Micron, CureVac Fall Premarket; Walgreens Rises Investing.com
02:34AM	CureVac Slides After COVID-19 Vaccine Effectiveness Just 48% TheStreet.com
02:15AM	CureVac Slumps After Confirming COVID Vaccine Candidate Only 48% Effective Investing.com
02:00AM	RPT-UPDATE 1-CureVac COVID-19 vaccine records only 48% efficacy in final trial readout Reuters
Jun-30-21 04:59PM	UPDATE 1-CureVac COVID-19 vaccine records only 48% efficacy in final trial readout Reuters +8.92%
04:45PM	CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60 ACCESSWIRE
04:30PM	CureVac COVID-19 vaccine records only 48% efficacy in final trial readout Reuters
11:13AM	Two weeks after its COVID vaccine flop, CureVacs stock is on the rise Fortune
07:12AM	CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R) ACCESSWIRE
Jun-29-21 07:19AM	Without a Coronavirus Vaccine Of Its Own, Is There Any Hope For CureVac Stock? Motley Fool +6.05%
Jun-25-21 12:35AM	CureVac Announces Voting Results of General Meeting ACCESSWIRE +5.86%
Jun-23-21 11:08AM	Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More Zacks
07:45AM	CureVac Provides Supervisory Board Update ACCESSWIRE
06:00AM	Could CureVac Be a Millionaire-Maker Stock? Motley Fool
05:55AM	How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges Motley Fool
Jun-22-21 05:52AM	Why Moderna Just Booked Another $3 Billion in Vaccine Orders and No One Cared Motley Fool
Jun-21-21 07:29AM	Germany's BaFin looking into possible insider trading of CureVac shares Reuters
06:13AM	Why Is Everyone Talking About CureVac Stock? Motley Fool
04:09AM	Amazon, CureVac Rise Premarket; Coinbase Global Falls Investing.com
Jun-18-21 10:54AM	CureVac Shares Are Soaring Because the Company Wont Give Up on a Covid-19 Vaccine Barrons.com +7.11%
10:40AM	UPDATE 1-Delta COVID variant becoming globally dominant, WHO official says Reuters
06:30AM	12 Words From CureVac's CEO That Could Mean Billions for Moderna and Pfizer Motley Fool
06:18AM	Curevac shares climb 10%; CFO says not giving up on COVID-19 vaccine MarketWatch
Jun-17-21 04:46PM	CureVac Stock Fell 39% After Its Vaccine Failure. The Pain May Just Be Getting Started. Barrons.com -38.99%
04:29PM	U.K. Cases Surge; BofA Sets Office Return Plan: Virus Update Bloomberg
04:13PM	CureVac Stock Plummets After Covid Vaccine Fails In Interim Analysis Investor's Business Daily
04:01PM	US STOCKS-Tech stocks drive Nasdaq to higher close, as hawkish Fed limits S&P Reuters
03:55PM	UPDATE 1-CureVac may let contractors make rival vaccines if own shot fails -CEO Reuters
12:36PM	Is CureVac Stock Still a Buy Following Disappointing COVID-19 Vaccine Data? TipRanks
12:14PM	CureVac may let contractors make rival vaccines if own shot fails - CEO Reuters
11:20AM	UPDATE 1-European regulator EMA says it won't set 50% efficacy threshold for COVID shots Reuters
11:06AM	Why CureVac Stock Is Getting Crushed Today Motley Fool
10:41AM	CureVac Delivers Unsatisfactory Vaccine Efficacy Results; Shares Fall 45% SmarterAnalyst
10:32AM	CureVac says its COVID vaccine was poor match against 29 COVID variants, as global case tally tops 177 million MarketWatch
10:30AM	CureVac (CVAC) Plummets on Disappointing COVID-19 Vaccine Data Zacks
10:26AM	TikTok owner ByteDances rapid growth, Nadella joins Microsoft board, Gates-backed vaccine fails Yahoo Finance Video
10:19AM	Pfizer Covid-19 Vaccine Could See Blockbuster Sales for Years Barrons.com
08:35AM	Thursdays Pre-Market: Heres What You Need to Know Before the Market Opens TipRanks
08:17AM	Dow Jones Futures Fall On Fed Rate-Hike Losses; Goldman In Buy Range, Covid Vaccine Play CureVac Crashes Investor's Business Daily
07:08AM	CureVac Is Down But Not Out: Here's How to Trade It TheStreet.com
06:44AM	CureVac tumbles 41% in premarket on COVID-19 vaccine disappointment MarketWatch
06:25AM	Coronavirus tally: Global cases of COVID-19 top 177 million and CureVac vaccine is just 47% effective MarketWatch
05:07AM	Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data Benzinga
05:04AM	Premarket Movers Thursday: CureVac, Midatech Pharma, Honest Co. TheStreet.com
04:09AM	UPDATE 1-European shares slip from record highs on hawkish Fed; CureVac sinks Reuters
04:01AM	CureVac, AstraZeneca Fall Premarket; Ford Rises Investing.com
02:27AM	CureVac Shares Plunge After Disappointing Late-Stage COVID Vaccine Trial TheStreet.com
01:20AM	CureVac Tanks As Potential Covid Vaccine Fails Trial Investing.com
01:13AM	Federal Reserve, Microsoft's Nadella, CureVac - 5 Things You Must Know TheStreet.com
Jun-16-21 08:00PM	CureVacs mRNA Covid vaccine falls short on efficacy in clinical trials Financial Times
07:31PM	CureVac Started the Day Worth More Than Novavax. Then Its Vaccine News Hit. Barrons.com
05:47PM	CureVacs COVID vaccine candidate 47% effective, stock tanks MarketWatch
05:00PM	CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV ACCESSWIRE
02:06PM	CureVac Says COVID Vaccine Candidate Didn't Meet Criteria TheStreet.com
Jun-11-21 11:23AM	CureVac Stock Drops on Worries Over Vaccine Trial Delay Barrons.com -7.54%
Jun-10-21 08:00PM	The next generation Covid-19 vaccines seeking a slice of the market Financial Times

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tubingen, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience